Literature DB >> 31506196

Normal tissue complication probability (NTCP) models for modern radiation therapy.

Giuseppe Palma1, Serena Monti1, Manuel Conson2, Roberto Pacelli2, Laura Cella3.   

Abstract

Mathematical models of normal tissue complication probability (NTCP) able to robustly predict radiation-induced morbidities (RIM) play an essential role in the identification of a personalized optimal plan, and represent the key to maximizing the benefits of technological advances in radiation therapy (RT). Most modern RT techniques pose, however, new challenges in estimating the risk of RIM. The aim of this report is to schematically review NTCP models in the framework of advanced radiation therapy techniques. Issues relevant to hypofractionated stereotactic body RT and ion beam therapy are critically reviewed. Reirradiation scenarios for new or recurrent malignances and NTCP are also illustrated. A new phenomenological approach to predict RIM is suggested.
Copyright © 2019 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Hadron therapy; Hypofractionation; Image-based outcomes; NTCP; Radiation-induced morbidity; Reirradiation; SBRT; Voxel-based analysis

Mesh:

Year:  2019        PMID: 31506196     DOI: 10.1053/j.seminoncol.2019.07.006

Source DB:  PubMed          Journal:  Semin Oncol        ISSN: 0093-7754            Impact factor:   4.929


  8 in total

Review 1.  Mechanisms and Review of Clinical Evidence of Variations in Relative Biological Effectiveness in Proton Therapy.

Authors:  Harald Paganetti
Journal:  Int J Radiat Oncol Biol Phys       Date:  2021-08-15       Impact factor: 8.013

2.  Radiation Therapy in Thoracic Tumors: Recent Trends and Current Issues.

Authors:  Laura Cella; Giuseppe Palma
Journal:  Cancers (Basel)       Date:  2022-05-30       Impact factor: 6.575

3.  Probing thoracic dose patterns associated to pericardial effusion and mortality in patients treated with photons and protons for locally advanced non-small-cell lung cancer.

Authors:  Laura Cella; Serena Monti; Ting Xu; Raffaele Liuzzi; Arnaldo Stanzione; Marco Durante; Radhe Mohan; Zhongxing Liao; Giuseppe Palma
Journal:  Radiother Oncol       Date:  2021-05-09       Impact factor: 6.901

4.  Practicalities in running early-phase trials using the time-to-event continual reassessment method (TiTE-CRM) for interventions with long toxicity periods using two radiotherapy oncology trials as examples.

Authors:  Erik van Werkhoven; Samantha Hinsley; Eleni Frangou; Jane Holmes; Rosemarie de Haan; Maria Hawkins; Sarah Brown; Sharon B Love
Journal:  BMC Med Res Methodol       Date:  2020-06-22       Impact factor: 4.615

5.  Radiation-Induced Esophagitis in Non-Small-Cell Lung Cancer Patients: Voxel-Based Analysis and NTCP Modeling.

Authors:  Serena Monti; Ting Xu; Radhe Mohan; Zhongxing Liao; Giuseppe Palma; Laura Cella
Journal:  Cancers (Basel)       Date:  2022-04-05       Impact factor: 6.639

Review 6.  Artificial Intelligence Applications to Improve the Treatment of Locally Advanced Non-Small Cell Lung Cancers.

Authors:  Andrew Hope; Maikel Verduin; Thomas J Dilling; Ananya Choudhury; Rianne Fijten; Leonard Wee; Hugo Jwl Aerts; Issam El Naqa; Ross Mitchell; Marc Vooijs; Andre Dekker; Dirk de Ruysscher; Alberto Traverso
Journal:  Cancers (Basel)       Date:  2021-05-14       Impact factor: 6.639

Review 7.  Roadmap: proton therapy physics and biology.

Authors:  Harald Paganetti; Chris Beltran; Stefan Both; Lei Dong; Jacob Flanz; Keith Furutani; Clemens Grassberger; David R Grosshans; Antje-Christin Knopf; Johannes A Langendijk; Hakan Nystrom; Katia Parodi; Bas W Raaymakers; Christian Richter; Gabriel O Sawakuchi; Marco Schippers; Simona F Shaitelman; B K Kevin Teo; Jan Unkelbach; Patrick Wohlfahrt; Tony Lomax
Journal:  Phys Med Biol       Date:  2021-02-26       Impact factor: 4.174

8.  Radiation Pneumonitis in Thoracic Cancer Patients: Multi-Center Voxel-Based Analysis.

Authors:  Giuseppe Palma; Serena Monti; Roberto Pacelli; Zhongxing Liao; Joseph O Deasy; Radhe Mohan; Laura Cella
Journal:  Cancers (Basel)       Date:  2021-07-15       Impact factor: 6.639

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.